Zentaris AG

Patent Applications and Registrations

Patent applications and USPTO patent grants for Zentaris AG.The latest application filed is for "cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals".

Company Profile

0.16.8

Zentaris AG - Frankfurt am Main DE
Zentaris AG - Frankfurt DE
Zentaris AG - Zentaris GmbH
Zentaris AG - Dresden DE
Zentaris AG - Frankfurt/Main DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Trademarks

Patent Activity

Patent	Date
Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone Grant 7,378,522 - Strehlke , et al. May 27, 2	2008-05-27
Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) Grant 7,122,570 - Koppitz , et al. October 17, 2	2006-10-17
Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals App 20050267303 - Weinberger, Heinz ; et al.	2005-12-01
Heteroaryl derivatives and their use as medicaments App 20050245523 - Emig, Peter ; et al.	2005-11-03
Novel heteroaryl derivatives and their use as medicaments App 20050176744 - Emig, Peter ; et al.	2005-08-11
Heteroaryl derivatives and their use as medicaments Grant 6,890,926 - Emig , et al. May 10, 2	2005-05-10
Oligopeptide lyophilisate, their preparation and use Grant 6,863,891 - Engel , et al. March 8, 2	2005-03-08
Growth hormone secretagogues Grant 6,861,409 - Martinez , et al. March 1, 2	2005-03-01
Agents useful for inactivation of Ras subfamily proteins Grant 6,849,715 - Von Eichel-Streiber , et al. February 1, 2	2005-02-01
Growth hormone secretagogues App 20040229823 - Martinez, Jean ; et al.	2004-11-18
Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation Grant 6,812,243 - Mahboobi , et al. November 2, 2	2004-11-02
Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone Grant 6,790,858 - Strehlke , et al. September 14, 2	2004-09-14
Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds Grant 6,727,252 - McMahon , et al. April 27, 2	2004-04-27
Method of treatment of female infertility Grant 6,716,817 - Engel , et al. April 6, 2	2004-04-06
Heteroaryl derivatives and their use as medicaments Grant 6,706,722 - Emig , et al. March 16, 2	2004-03-16
Use of dopamine receptor antagonists in palliative tumor therapy Grant 6,696,428 - Nickel , et al. February 24, 2	2004-02-24
Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) App 20030232873 - Koppitz, Marcus Karl ; et al.	2003-12-18
Heteroary1 derivatives and their use as medicaments Grant 6,638,935 - Emig , et al. October 28, 2	2003-10-28
LHRH antagonists having improved solubility properties Grant 6,627,609 - Bernd , et al. September 30, 2	2003-09-30
Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds App 20030181480 - McMahon, Gerald ; et al.	2003-09-25
Novel phospholipid derivatives App 20030153533 - Nossner, Gerhard ; et al.	2003-08-14
Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis Grant 6,544,551 - Engel , et al. April 8, 2	2003-04-08
Oligopeptide lyophilisate, their preparation and use App 20020198186 - Engel, Jurgen ; et al.	2002-12-26
Xanthone compounds, their preparation and use as medicament Grant 6,403,636 - Reutrakul , et al. June 11, 2	2002-06-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.